Difference between revisions of "Non-small cell lung cancer, MET-mutated"
Jump to navigation
Jump to search
m |
m (→Chemotherapy) |
||
| Line 40: | Line 40: | ||
====Biomarker Eligibility Criteria==== | ====Biomarker Eligibility Criteria==== | ||
*Biomarker: MET exon 14 skipping | *Biomarker: MET exon 14 skipping | ||
| − | ==== | + | ====Targeted therapy==== |
*[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food | *[[Capmatinib (Tabrecta)]] 400 mg PO twice per day with or without food | ||
Revision as of 01:38, 30 July 2020
| Page editor | Section editor | ||
|---|---|---|---|
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN  AmitKulkarniMD
|
 |
Travis Osterman, DO, MS Vanderbilt University Nashville, TN TravisOsterman |
Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease
Capmatinib monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Wolf et al. 2019 (GEOMETRY mono-1) | Phase II (RT) |
Biomarker Eligibility Criteria
- Biomarker: MET exon 14 skipping
Targeted therapy
- Capmatinib (Tabrecta) 400 mg PO twice per day with or without food
Continued indefinitely
References
- Abstract: Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J.M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. link to abstract contains verified protocol DOI